Reduced intrapatient variability of cyclosporine pharmacokinetics in renal transplant recipients switched from oral Sandimmune to Neoral

Robert Mendez, Hanna Abboud, James Burdick, Brian Copley, Richard Freeman, Thomas D. Batiuk, Gerard F. Cooney, Ralph Barbeito

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Sixty-six renal transplant patients maintained on Sandimmune®, the traditional formulation of cyclosporine, participated in an open-label, sequential trial to compare intrapatient variability in drug exposure before and after a switch to Neoral®. Three 12-hour cyclosporine pharmacokinetic profiles were obtained over approximately 6 weeks while patients were receiving Sandimmune. Patients were then switched to Neoral, with the dose adjusted as necessary to maintain target trough blood cyclosporine concentrations. At approximately 4 and 6 weeks postconversion, 2 additional pharmacokinetic profiles were obtained. Key pharmacokinetic variables analyzed were area under the concentration-time curve (AUC), maximum concentration (C(max)), and predose trough concentration (C0). Intrapatient variability in drug exposure for dose-normalized mean AUC, C(max), and C0 was significantly reduced with Neoral, with 50 (76%), 57 (86%), and 45 (68%) patients experiencing reduced variability in AUC, C(max) and C0, respectively (P < 0.001). Additionally, the total exposure to cyclosporine was more predictable from the trough level of cyclosporine with Neoral; the relationship between AUC and C0 was 0.81 for Neoral at both pharmacokinetic profiling time points but ranged from 0.49 to 0.69 for the 3 Sandimmune time points. The large reductions in intrapatient variability of pharmacokinetic variables for cyclosporine provided by Neoral indicate an improvement in the consistency of drug exposure, which may translate into important clinical benefits.

Original languageEnglish (US)
Pages (from-to)160-171
Number of pages12
JournalClinical Therapeutics
Volume21
Issue number1
DOIs
StatePublished - 1999

Fingerprint

Cyclosporine
Pharmacokinetics
Kidney
Transplant Recipients
Pharmaceutical Preparations

Keywords

  • Bioavailability
  • Cyclosporine
  • Pharmacokinetics
  • Transplant

ASJC Scopus subject areas

  • Pharmacology

Cite this

Reduced intrapatient variability of cyclosporine pharmacokinetics in renal transplant recipients switched from oral Sandimmune to Neoral. / Mendez, Robert; Abboud, Hanna; Burdick, James; Copley, Brian; Freeman, Richard; Batiuk, Thomas D.; Cooney, Gerard F.; Barbeito, Ralph.

In: Clinical Therapeutics, Vol. 21, No. 1, 1999, p. 160-171.

Research output: Contribution to journalArticle

Mendez, R, Abboud, H, Burdick, J, Copley, B, Freeman, R, Batiuk, TD, Cooney, GF & Barbeito, R 1999, 'Reduced intrapatient variability of cyclosporine pharmacokinetics in renal transplant recipients switched from oral Sandimmune to Neoral', Clinical Therapeutics, vol. 21, no. 1, pp. 160-171. https://doi.org/10.1016/S0149-2918(00)88276-4
Mendez, Robert ; Abboud, Hanna ; Burdick, James ; Copley, Brian ; Freeman, Richard ; Batiuk, Thomas D. ; Cooney, Gerard F. ; Barbeito, Ralph. / Reduced intrapatient variability of cyclosporine pharmacokinetics in renal transplant recipients switched from oral Sandimmune to Neoral. In: Clinical Therapeutics. 1999 ; Vol. 21, No. 1. pp. 160-171.
@article{67a385272be54b5e9d1fdb606a92594d,
title = "Reduced intrapatient variability of cyclosporine pharmacokinetics in renal transplant recipients switched from oral Sandimmune to Neoral",
abstract = "Sixty-six renal transplant patients maintained on Sandimmune{\circledR}, the traditional formulation of cyclosporine, participated in an open-label, sequential trial to compare intrapatient variability in drug exposure before and after a switch to Neoral{\circledR}. Three 12-hour cyclosporine pharmacokinetic profiles were obtained over approximately 6 weeks while patients were receiving Sandimmune. Patients were then switched to Neoral, with the dose adjusted as necessary to maintain target trough blood cyclosporine concentrations. At approximately 4 and 6 weeks postconversion, 2 additional pharmacokinetic profiles were obtained. Key pharmacokinetic variables analyzed were area under the concentration-time curve (AUC), maximum concentration (C(max)), and predose trough concentration (C0). Intrapatient variability in drug exposure for dose-normalized mean AUC, C(max), and C0 was significantly reduced with Neoral, with 50 (76{\%}), 57 (86{\%}), and 45 (68{\%}) patients experiencing reduced variability in AUC, C(max) and C0, respectively (P < 0.001). Additionally, the total exposure to cyclosporine was more predictable from the trough level of cyclosporine with Neoral; the relationship between AUC and C0 was 0.81 for Neoral at both pharmacokinetic profiling time points but ranged from 0.49 to 0.69 for the 3 Sandimmune time points. The large reductions in intrapatient variability of pharmacokinetic variables for cyclosporine provided by Neoral indicate an improvement in the consistency of drug exposure, which may translate into important clinical benefits.",
keywords = "Bioavailability, Cyclosporine, Pharmacokinetics, Transplant",
author = "Robert Mendez and Hanna Abboud and James Burdick and Brian Copley and Richard Freeman and Batiuk, {Thomas D.} and Cooney, {Gerard F.} and Ralph Barbeito",
year = "1999",
doi = "10.1016/S0149-2918(00)88276-4",
language = "English (US)",
volume = "21",
pages = "160--171",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "1",

}

TY - JOUR

T1 - Reduced intrapatient variability of cyclosporine pharmacokinetics in renal transplant recipients switched from oral Sandimmune to Neoral

AU - Mendez, Robert

AU - Abboud, Hanna

AU - Burdick, James

AU - Copley, Brian

AU - Freeman, Richard

AU - Batiuk, Thomas D.

AU - Cooney, Gerard F.

AU - Barbeito, Ralph

PY - 1999

Y1 - 1999

N2 - Sixty-six renal transplant patients maintained on Sandimmune®, the traditional formulation of cyclosporine, participated in an open-label, sequential trial to compare intrapatient variability in drug exposure before and after a switch to Neoral®. Three 12-hour cyclosporine pharmacokinetic profiles were obtained over approximately 6 weeks while patients were receiving Sandimmune. Patients were then switched to Neoral, with the dose adjusted as necessary to maintain target trough blood cyclosporine concentrations. At approximately 4 and 6 weeks postconversion, 2 additional pharmacokinetic profiles were obtained. Key pharmacokinetic variables analyzed were area under the concentration-time curve (AUC), maximum concentration (C(max)), and predose trough concentration (C0). Intrapatient variability in drug exposure for dose-normalized mean AUC, C(max), and C0 was significantly reduced with Neoral, with 50 (76%), 57 (86%), and 45 (68%) patients experiencing reduced variability in AUC, C(max) and C0, respectively (P < 0.001). Additionally, the total exposure to cyclosporine was more predictable from the trough level of cyclosporine with Neoral; the relationship between AUC and C0 was 0.81 for Neoral at both pharmacokinetic profiling time points but ranged from 0.49 to 0.69 for the 3 Sandimmune time points. The large reductions in intrapatient variability of pharmacokinetic variables for cyclosporine provided by Neoral indicate an improvement in the consistency of drug exposure, which may translate into important clinical benefits.

AB - Sixty-six renal transplant patients maintained on Sandimmune®, the traditional formulation of cyclosporine, participated in an open-label, sequential trial to compare intrapatient variability in drug exposure before and after a switch to Neoral®. Three 12-hour cyclosporine pharmacokinetic profiles were obtained over approximately 6 weeks while patients were receiving Sandimmune. Patients were then switched to Neoral, with the dose adjusted as necessary to maintain target trough blood cyclosporine concentrations. At approximately 4 and 6 weeks postconversion, 2 additional pharmacokinetic profiles were obtained. Key pharmacokinetic variables analyzed were area under the concentration-time curve (AUC), maximum concentration (C(max)), and predose trough concentration (C0). Intrapatient variability in drug exposure for dose-normalized mean AUC, C(max), and C0 was significantly reduced with Neoral, with 50 (76%), 57 (86%), and 45 (68%) patients experiencing reduced variability in AUC, C(max) and C0, respectively (P < 0.001). Additionally, the total exposure to cyclosporine was more predictable from the trough level of cyclosporine with Neoral; the relationship between AUC and C0 was 0.81 for Neoral at both pharmacokinetic profiling time points but ranged from 0.49 to 0.69 for the 3 Sandimmune time points. The large reductions in intrapatient variability of pharmacokinetic variables for cyclosporine provided by Neoral indicate an improvement in the consistency of drug exposure, which may translate into important clinical benefits.

KW - Bioavailability

KW - Cyclosporine

KW - Pharmacokinetics

KW - Transplant

UR - http://www.scopus.com/inward/record.url?scp=0033048295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033048295&partnerID=8YFLogxK

U2 - 10.1016/S0149-2918(00)88276-4

DO - 10.1016/S0149-2918(00)88276-4

M3 - Article

C2 - 10090433

AN - SCOPUS:0033048295

VL - 21

SP - 160

EP - 171

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 1

ER -